CLINICAL TRIALS PROFILE FOR FARYDAK
✉ Email this page to a colleague
All Clinical Trials for farydak
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00859222 ↗ | LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma | Completed | Beth Israel Deaconess Medical Center | Phase 1/Phase 2 | 2009-03-01 | The purpose of this research study is to determine the amount of LBH589 that can be given to people safely when LBH589 is given in combination with bevacizumab. LBH589 in combination with bevacizumab is a drug combination that may stop cancer cells from growing abnormally. LBH589 has been used alone in other trials for solid tumor malignancies. Bevacizumab is FDA approved for use in patients with colorectal cancer and has been studied extensively in other types of solid tumors. The combination of LBH589 and bevacizumab has not yet been studied but information from other studies suggests that the combination may help prevent the growth of the participant's tumor. |
| NCT00859222 ↗ | LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma | Completed | Brigham and Women's Hospital | Phase 1/Phase 2 | 2009-03-01 | The purpose of this research study is to determine the amount of LBH589 that can be given to people safely when LBH589 is given in combination with bevacizumab. LBH589 in combination with bevacizumab is a drug combination that may stop cancer cells from growing abnormally. LBH589 has been used alone in other trials for solid tumor malignancies. Bevacizumab is FDA approved for use in patients with colorectal cancer and has been studied extensively in other types of solid tumors. The combination of LBH589 and bevacizumab has not yet been studied but information from other studies suggests that the combination may help prevent the growth of the participant's tumor. |
| NCT00859222 ↗ | LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma | Completed | Genentech, Inc. | Phase 1/Phase 2 | 2009-03-01 | The purpose of this research study is to determine the amount of LBH589 that can be given to people safely when LBH589 is given in combination with bevacizumab. LBH589 in combination with bevacizumab is a drug combination that may stop cancer cells from growing abnormally. LBH589 has been used alone in other trials for solid tumor malignancies. Bevacizumab is FDA approved for use in patients with colorectal cancer and has been studied extensively in other types of solid tumors. The combination of LBH589 and bevacizumab has not yet been studied but information from other studies suggests that the combination may help prevent the growth of the participant's tumor. |
| NCT00859222 ↗ | LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma | Completed | Massachusetts General Hospital | Phase 1/Phase 2 | 2009-03-01 | The purpose of this research study is to determine the amount of LBH589 that can be given to people safely when LBH589 is given in combination with bevacizumab. LBH589 in combination with bevacizumab is a drug combination that may stop cancer cells from growing abnormally. LBH589 has been used alone in other trials for solid tumor malignancies. Bevacizumab is FDA approved for use in patients with colorectal cancer and has been studied extensively in other types of solid tumors. The combination of LBH589 and bevacizumab has not yet been studied but information from other studies suggests that the combination may help prevent the growth of the participant's tumor. |
| NCT00859222 ↗ | LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma | Completed | Northwestern University | Phase 1/Phase 2 | 2009-03-01 | The purpose of this research study is to determine the amount of LBH589 that can be given to people safely when LBH589 is given in combination with bevacizumab. LBH589 in combination with bevacizumab is a drug combination that may stop cancer cells from growing abnormally. LBH589 has been used alone in other trials for solid tumor malignancies. Bevacizumab is FDA approved for use in patients with colorectal cancer and has been studied extensively in other types of solid tumors. The combination of LBH589 and bevacizumab has not yet been studied but information from other studies suggests that the combination may help prevent the growth of the participant's tumor. |
| NCT00859222 ↗ | LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma | Completed | Novartis | Phase 1/Phase 2 | 2009-03-01 | The purpose of this research study is to determine the amount of LBH589 that can be given to people safely when LBH589 is given in combination with bevacizumab. LBH589 in combination with bevacizumab is a drug combination that may stop cancer cells from growing abnormally. LBH589 has been used alone in other trials for solid tumor malignancies. Bevacizumab is FDA approved for use in patients with colorectal cancer and has been studied extensively in other types of solid tumors. The combination of LBH589 and bevacizumab has not yet been studied but information from other studies suggests that the combination may help prevent the growth of the participant's tumor. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for farydak
Condition Name
Clinical Trial Locations for farydak
Trials by Country
Clinical Trial Progress for farydak
Clinical Trial Phase
Clinical Trial Sponsors for farydak
Sponsor Name
